Core Insights - The "Annual Outstanding Biopharmaceutical Enterprises" award recognizes companies with independent core technologies, continuous innovation, and effective transformation of research results into clinical or commercial applications [4] Group 1: Award Announcement - The "Annual Outstanding Biopharmaceutical Enterprises" award was announced during the "Technology Empowerment, Capital Breakthrough" sharing session held online by Gelonghui on December 22 [1] - Eight companies were awarded, including Baillie Tianheng (688506.SH), Dongyang Sunshine Pharmaceutical (06887.HK), Dongyao Pharmaceutical-B (01875.HK), and others, listed in alphabetical order [1] Group 2: Evaluation Criteria - The evaluation for the award was based on a comprehensive assessment of technical innovation, research and development strength, and achievement transformation [4] - The final results were derived through quantitative data analysis and expert review [4] Group 3: Purpose of the Award - Gelonghui aims to create a reference value ranking for listed companies and unicorns in the investment community with the "Golden Gelong Award" [4] - The award covers all listed companies and unicorns on major exchanges including the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, New York Stock Exchange, and NASDAQ [4]

Core Insights - The "Annual Outstanding Biopharmaceutical Enterprises" award recognizes companies with independent core technologies, continuous innovation, and effective transformation of research results into clinical or commercial applications [4] Group 1: Award Announcement - The "Annual Outstanding Biopharmaceutical Enterprises" award will be announced during the "Technology Empowerment, Capital Breakthrough" sharing session held online by Gelonghui on December 22 [1] - Eight companies, including Baillie Gifford (688506.SH), Dongyang Sunshine Pharmaceutical (06887.HK), Dongyao Pharmaceutical-B (01875.HK), and others, have been awarded the title [1] Group 2: Evaluation Criteria - The evaluation for the award is based on a comprehensive assessment of technical innovation, research and development strength, and achievement transformation [4] - The final results were determined through quantitative data analysis and an expert review panel [4] Group 3: Purpose of the Award - Gelonghui aims to create a reference value ranking for listed companies and unicorns in the investment community with the "Golden Gelong Award" [4] - The award covers all listed companies and unicorns on major exchanges, including the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, New York Stock Exchange, and NASDAQ [4]

东曜药业-B(01875)公布，2025年12月19日，管理委员会已议决根据2024年受限制股份奖励计划作出授 出，共涉及1335万股奖励股份，每股奖励股份0.6港元。 ...

智通财经APP讯，东曜药业-B(01875)公布，2025年12月19日，管理委员会已议决根据2024年受限制股份 奖励计划作出授出，共涉及1335万股奖励股份，每股奖励股份0.6港元。 ...

茲提述日期為2024年5月30日 的2024年計劃通函及本公司日期為2024年6月26日 的 股 東 週 年 大 會 投 票 表 決 結 果 公 告，內 容 有 關（其 中 包 括）採 納2024年受限制股 份 獎 勵 計 劃。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 BioDlink International Company Limited 東曜藥業股份有限公司 （於 香 港 註 冊 成 立 的 有 限 公 司） （股 份 代 號：1875） 根 據2024年受限制股份獎勵計劃 授出獎勵股份 緒 言 本公告根據上市規則第17.06A、17.06B及17.06C條 而 作 出。 在2024年 受 限 制 股 份 獎 勵 計 劃 規 則 的 規 限 下，向 經 選 定參與者授出的任何獎勵股份將於下列日期最晚者歸 屬 該 經 選 定 參 與 者：(i)有 關 該 獎 勵 股 份 的 歸 屬 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年11月30日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 東曜藥業股份有限公司 | | | 呈交日期: | 2025年12月4日 | | | I. 法定/註冊股本變動 不適用 | | | FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01875 | 說明 | | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | | 已發行股份總數 | | | 上月底結存 | | | 772,787,887 | | | 0 | | 772,787,887 | | 增加 / 減少 ( ...

Core Insights - Dongyao Pharmaceutical reported a revenue of 622 million yuan for the nine months ending September 30, 2025, representing a 23% decrease compared to the same period last year, primarily due to intensified market competition for self-developed products [1] - The company experienced a net loss of 3.37 million yuan during this period, contrasting with a net profit of 35.4 million yuan in the same period last year [1] - As of September 30, 2025, the company's current assets totaled 656 million yuan, non-current assets were 721 million yuan, current liabilities amounted to 266 million yuan, non-current liabilities were 385 million yuan, and total net assets slightly decreased to 726 million yuan from 730 million yuan as of December 31, 2024 [1] Financial Performance - Revenue for the nine-month period was 622 million yuan, down 23% year-on-year [1] - Net loss recorded was 3.37 million yuan, compared to a net profit of 35.4 million yuan in the previous year [1] - Total net assets decreased slightly to 726 million yuan from 730 million yuan [1] Balance Sheet Overview - Current assets stood at 656 million yuan [1] - Non-current assets were reported at 721 million yuan [1] - Current liabilities were 266 million yuan, while non-current liabilities were 385 million yuan [1]

Group 1 - The Hong Kong stock market opened slightly higher today, with the Hang Seng Index at 26,754.93 points, up 58.52 points, or 0.22% [1] - The Hang Seng Technology Index rose to 5,939.69 points, increasing by 15.30 points, or 0.26% [3] Group 2 - HeSai-W (HK02525) reported a net income of RMB 795 million for Q3, a year-on-year increase of 47.5%, and a net profit of RMB 256 million, turning from loss to profit. The full-year net profit guidance has been raised to between RMB 350 million and RMB 450 million, with Q4 revenue expected to be between RMB 1 billion and RMB 1.2 billion, a year-on-year growth of approximately 39% to 67% [2] - China General Nuclear Power New Energy (HK01811) announced a cumulative power generation of 15,753.4 GWh for the first ten months, a year-on-year decrease of 3.5% [6] - Dongyao Pharmaceutical-B (HK01875) reported a revenue of RMB 622 million for the nine months ending September 30, 2025, with a net loss attributable to equity holders of RMB 3.371 million [6] Group 3 - The innovative drug sector saw a collective rise in early trading, with companies like BeiGene up over 4%, Kailaiying up over 1.8%, and others like Zhaoyan New Drug, WuXi AppTec, and WuXi Biologics rising over 1% [6] - In the tech sector, Xiaomi rose over 2%, while Tencent and NetEase increased by over 1%. However, Alibaba and Baidu fell by over 2% [8]

Core Insights - Dongyao Pharmaceutical-B (01875) reported a revenue of RMB 622 million for the nine-month period ending September 30, 2025, indicating the company's financial performance during this timeframe [1] - The company recorded a net loss attributable to equity holders of RMB 3.371 million during the same period, highlighting ongoing financial challenges [1] Financial Performance - Revenue for the nine-month period was RMB 622 million, reflecting the company's operational scale [1] - The net loss for the period was RMB 3.371 million, which indicates a negative financial outcome for equity holders [1]

Core Viewpoint - Dongyao Pharmaceutical-B (01875.HK) reported a significant decline in revenue for the first three quarters of the fiscal year ending September 30, 2025, with a year-on-year decrease of approximately 23.15% [1] Financial Performance - Revenue for the first three quarters was approximately RMB 622 million [1] - The company recorded a net loss of RMB 3.37 million [1]